Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report

Patients with acute myeloid leukemia (AML) who have comorbidities have limited treatment options, thereby resulting in poor prognosis. Venetoclax, a specific B‐cell lymphoma‐2 inhibitor, has recently been approved for AML in combination with hypomethylating agents; however, only one report has descr...

Descripción completa

Detalles Bibliográficos
Autores principales: Akagi, Yuina, Yamashita, Yusuke, Kosako, Hideki, Furuya, Yoshiaki, Hosoi, Hiroki, Mushino, Toshiki, Murata, Shogo, Nishikawa, Akinori, Tamura, Shinobu, Nakao, Taisei, Sonoki, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435694/
https://www.ncbi.nlm.nih.gov/pubmed/37601888
http://dx.doi.org/10.1002/jha2.732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435694/
https://www.ncbi.nlm.nih.gov/pubmed/37601888
http://dx.doi.org/10.1002/jha2.732

Ejemplares similares